Tokyo Tape
Sign in
← Takeda Pharmaceutical

Annual report

4502.TEDINET S100TNTP
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥4.26T2023-04-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥4.03T2022-04-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥3.57T2021-04-01 → 2022-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥3.20T2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥3.29T2019-04-01 → 2020-03-31dCons.Revenue IFRS (5-year summary)
Operating income¥214.1bn2023-04-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥490.5bn2022-04-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥52.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥375.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥302.6bn2021-04-01 → 2022-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥366.2bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥60.8bn2019-04-01 → 2020-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥144.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥317.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥230.1bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥376.0bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥44.2bn2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥144.2bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥317.0bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥230.2bn2021-04-01 → 2022-03-31dCons.Profit loss IFRS (5-year summary)
Net income¥376.2bn2020-04-01 → 2021-03-31dCons.Profit loss IFRS (5-year summary)
Net income¥44.3bn2019-04-01 → 2020-03-31dCons.Profit loss IFRS (5-year summary)
Total assets¥15.11Tat 2024-03-31Cons.Assets IFRS
Total assets¥13.96Tat 2023-03-31Cons.Assets IFRS
Total assets¥13.18Tat 2022-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥12.91Tat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥12.82Tat 2020-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥7.83Tat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥7.60Tat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥7.27Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥6.35Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥5.68Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥7.27Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥6.35Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Cash & equivalents¥457.8bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥533.5bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥849.7bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥966.2bnat 2021-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥637.6bnat 2020-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥716.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥977.2bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥1.12T2021-04-01 → 2022-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.01T2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥669.8bn2019-04-01 → 2020-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥463.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥607.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥198.1bn2021-04-01 → 2022-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥393.5bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥292.1bn2019-04-01 → 2020-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥354.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥709.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥1.07T2021-04-01 → 2022-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.09T2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.01T2019-04-01 → 2020-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥92.092023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥204.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥147.142021-04-01 → 2022-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥240.722020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥28.412019-04-01 → 2020-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥91.162023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥201.942022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥145.872021-04-01 → 2022-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥238.962020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥28.252019-04-01 → 2020-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥4,635.56at 2024-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,087.49at 2023-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,665.61at 2022-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,308.93at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,032.22at 2020-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio48.1%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio45.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio43.1%at 2022-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio40.1%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio36.8%at 2020-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE2.1%2023-04-01 → 2024-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE5.3%2022-04-01 → 2023-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE4.2%2021-04-01 → 2022-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE7.6%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE0.9%2019-04-01 → 2020-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees49,281at 2024-03-31Cons.Number of employees
Employees49,095at 2023-03-31Cons.Number of employees
Employees47,347at 2022-03-31dCons.Number of employees
Employees47,099at 2021-03-31dCons.Number of employees
Employees47,495at 2020-03-31dCons.Number of employees
Revenue¥595.6bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥632.1bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥764.3bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥602.6bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥616.3bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥48.1bn2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥136.1bn2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥286.4bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥340.1bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥550.9bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥50.0bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥72.3bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥391.3bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥383.0bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥338.9bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥330.6bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥324.4bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥247.5bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥130.6bn2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥9.76Tat 2024-03-31StandaloneAssets
Total assets¥9.41Tat 2023-03-31StandaloneAssets
Total assets¥9.64Tat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥10.86Tat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥10.29Tat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥5.67Tat 2024-03-31StandaloneLiabilities
Total liabilities¥5.20Tat 2023-03-31StandaloneLiabilities
Net assets / equity¥4.09Tat 2024-03-31StandaloneNet assets
Net assets / equity¥4.21Tat 2023-03-31StandaloneNet assets
Net assets / equity¥4.29Tat 2022-03-31dStandaloneNet assets
Net assets / equity¥4.43Tat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥4.55Tat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥130.9bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥164.9bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥216.62023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥213.062022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥207.52021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥158.452020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥83.882019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥216.562023-04-01 → 2024-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥213.052022-04-01 → 2023-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥207.52021-04-01 → 2022-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥158.442020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥83.872019-04-01 → 2020-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1882023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1802022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1802021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1802020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1802019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥2,604.87at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,704.87at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,769.31at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,835.81at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,919.21at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio41.9%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio44.7%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio44.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio40.8%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio44.2%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE8.2%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE7.8%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE7.4%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE5.5%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE2.8%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued1,582,419,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,296,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,253,000at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,576,388,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,576,374,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees5,474at 2024-03-31StandaloneNumber of employees
Employees5,486at 2023-03-31StandaloneNumber of employees
Employees5,149at 2022-03-31dStandaloneNumber of employees
Employees4,966at 2021-03-31dStandaloneNumber of employees
Employees5,350at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2024-03-3149281 pure
Pharmaceutical Businessreportable segmentemployeesat 2024-03-315474 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,742
ItemContextValueUnit
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当なし
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当なし
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目１番１号(武田薬品工業株式会社武田グローバル本社)
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京(3278)2111(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)グローバルファイナンス　チーフアカウンティングオフィサー＆コーポレートコントローラー　竹田 徳正
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00919
Fund codeFilingDateInstant－
Security codeFilingDateInstant45020
Filer name in japaneseFilingDateInstant
Original text (Japanese)武田薬品工業株式会社
Filer name in englishFilingDateInstantTakeda Pharmaceutical Company Limited
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2023-04-01
Current period end dateFilingDateInstant2024-03-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2024-03-31
Previous fiscal year start dateFilingDateInstant2022-04-01
Comparative period end dateFilingDateInstant2023-03-31
Previous fiscal year end dateFilingDateInstant2023-03-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant－
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Business results of reporting company (text)FilingDateInstantText · Plus
Company history (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Overview of affiliated entities (text)FilingDateInstantText · Plus
Information about employees (text)FilingDateInstantText · Plus
Business policy business environment issues to address etc (text)FilingDateInstantText · Plus
Disclosure of sustainability related financial information (text)FilingDateInstantText · Plus
Governance (text)FilingDateInstantText · Plus
Reference to other information governanceFilingDateInstantText · Plus
Strategy (text)FilingDateInstantText · Plus
Reference to other information strategyFilingDateInstant
Original text (Japanese)2024年統合報告書「PATINET すべての患者さんのために」
Policy on development of human resources and internal environment strategy (text)FilingDateInstantText · Plus
Reference to other information2 strategyFilingDateInstant
Original text (Japanese)2024年統合報告書「PEOPLE ともに働く仲間のために」
Risk management (text)FilingDateInstantText · Plus
Reference to other information risk managementFilingDateInstantText · Plus
Metrics and targets (text)FilingDateInstantText · Plus
Reference to other information metrics and targetsFilingDateInstant
Original text (Japanese)2024年統合報告書「サステナビリティにおける注力分野と指標」

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2023-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass